Evidence map›Paper›PMID 36732171›Full record

ReviewThe Journal of allergy and clinical immunology2023

Incorporating genetics in identifying peanut allergy risk and tailoring allergen immunotherapy: A perspective on the genetic findings from the LEAP trial.

Michelle F Huffaker, Kanika Kanchan, Henry T Bahnson, Carolyn Baloh, Gideon Lack, Gerald T Nepom, Rasika A Mathias

Open access · bronzeAbstract readReview
In one paragraph

Review in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Immunomodulatory metabolites in IgE-mediated food allergy and oral immunotherapy outcomes based on metabolomic profiling.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2024
    Article
  5. Breakdown and Repair of Peripheral Immune Tolerance in Type 1 Diabetes.Cold Spring Harbor perspectives in medicine · 2024
    Review
  6. Review
  7. Genetic and Immunological Pathogenesis of Atopic Dermatitis.The Journal of investigative dermatology · 2024
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Michelle F HuffakerImmune Tolerance Network, San Francisco, Calif.
Kanika KanchanDivision of Allergy and Clinical Immunology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Md.
Henry T BahnsonImmune Tolerance Network, Seattle, Wash; Benaroya Research Institute at Virginia Mason, Seattle, Wash.
Carolyn BalohImmune Tolerance Network, San Francisco, Calif; Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass.
Gideon LackDepartment of Pediatric Allergy, Division of Asthma, Allergy and Lung Biology, King's College London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Gerald T NepomImmune Tolerance Network, Seattle, Wash; Benaroya Research Institute at Virginia Mason, Seattle, Wash.
Rasika A MathiasDivision of Allergy and Clinical Immunology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Md. Electronic address: rmathias@jhmi.edu.
Johns Hopkins University · USVirginia Mason Medical Center · USBrigham and Women's Hospital · USImmune Tolerance Network · USKing's College London · GB

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
NIAID NIH HHS UM1 AI109565
6 · The paper itself

Abstract

Examining the genetics of peanut allergy (PA) in the context of clinical trial interventions and outcomes provides an opportunity to not only understand gene-environment interactions for PA risk but to also understand the benefit of allergen immunotherapy. A consistent theme in the genetics of food allergy is that in keeping with the dual allergen exposure hypothesis, barrier- and immune-related genes are most commonly implicated in food allergy and tolerance. With a focus on PA, we review how genetic risk factors across 3 genes (FLG, MALT1, and HLA-DQA1) have helped delineate distinct allergic characteristics and outcomes in the context of environmental interventions in the Learning Early about Peanut Allergy (LEAP) study and other clinical trials. We specifically consider and present a framework for genetic risk prediction for the development of PA and discuss how genetics, age, and oral consumption intertwine to predict PA outcome. Although there is some promise in this proposed framework, a better understanding of the mechanistic pathways by which PA develops and persists is needed to develop targeted therapeutics for established disease. Only by understanding the mechanisms by which PA develops, persists, and resolves can we identify adjuvants to oral immunotherapy to make older children and adults immunologically similar to their younger, more malleable counterparts and thus more likely to achieve long-term tolerance.

Indexed as

Food HypersensitivityPeanut HypersensitivityAdolescentAdultAllergensArachisChildDesensitization, ImmunologicHumansRisk FactorsAllergensatopic dermatitiseczemafilaggringeneticsHLAMALT1oral immunotherapyPeanut allergy

Identifiers

PMID36732171
PMCPMC12576930
OpenAlexW4318686612

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.